Scientific Poster Download

ADCs and XDCs are leading therapeutic innovations, but their success depends on solving two industry-wide conjugation challenges: heterogeneity from stochastic coupling and circulation instability of traditional maleimide linkers. Conventional interchain cysteine coupling, used in 13 of 18 commercial ADCs, struggles with both issues.

WuXi XDC addresses these gaps with three integrated technologies:

1.WuXiDARx™: A clinical‑validated platform targeting interchain cystines. It offers flexible DAR options (1, 2, 4, 6) with high homogeneity (85±5%/70±10%), boosts efficacy/safety, and supports native IgG1 as well as advanced ADC/XDC formats (dual‑payload, bispecific, AOCs, APCs). It is validated by 8 clinical ADCs, 10 CMC projects, and >2 kg batch sizes.

2.X‑LinC™: A linear connector technology featuring strong thiol reactivity and superior plasma stability, fully compatible with WuXiDARx™.

3.CysLink™: A rebridging connector technology offering exceptional plasma stability and reduced half‑Ab/thiol mismatches, also fully compatible with WuXiDARx™.

Collectively, WuXiDARx™, X‑LinC™, and CysLink form a robust, end‑to‑end solution that overcomes historical limitations, ensuring homogeneous, stable, and high‑quality bioconjugates. This technology stack is pivotal to empowering the development of next‑generation ADCs and XDCs.